Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand

Lauren H. Carlton¹, Tiffany Chen¹, Alana L. Whitcombe¹, Reuben McGregor¹, Greg Scheurich², Campbell R. Sheen³, James M. Dickson⁴, Chris Bullen⁵, Annie Chiang⁵, Daniel J. Exeter⁵, Janine Paynter⁵, Michael G. Baker⁶, Richard Charlewood², Nicole J. Moreland¹

¹School of Medical Sciences, The University of Auckland, Auckland, New Zealand

²The New Zealand Blood Service, Auckland, New Zealand

³Callaghan Innovation, Christchurch, New Zealand

⁴School of Biological Sciences, The University of Auckland, Auckland, New Zealand ⁵School of Population Health, The University of Auckland, Auckland, New Zealand ⁶University of Otago, Wellington, Department of Public Health

Correspondence: l.carlton@auckland.ac.nz

Background:

- New Zealand has a strategy of eliminating \bullet SARS-CoV-2 that has resulted in a low incidence of COVID-19.
- The spike protein is expressed on the surface of SARS-CoV-2. At the tip of the spike protein is the Receptor Binding Domain (RBD) which has been shown to be immunogenic and induces a long-lasting antibody response.³ This study investigates the seroprevalence of SARS-CoV-2 in New Zealand using spike-based assays and New Zealand blood donors as a sentinel population.



Spike

RBD





Demographics:

- Participants geographically spread, 16 of 20 district health regions represented.
- Compared to the 2018 New Zealand Census, participants:
 - more likely to be aged 40-59 years (43.3% vs 25.9%) and of European ethnicity (77.8% vs 61.0%).
- had a similar proportion of females (49.1% vs 50.7%).


2018 Census New Zealand Population (%)


New Zealand Blood Donor Study Population (%)


Methods:

- Due to the low number of reported cases of COVID-19 in New Zealand, the method was optimised for specificity.
- Samples (n=9806) were first screened on well-established spike based 2-step ELISA.² Samples above the cut-off were run on two commercial assays.

Samples were collected from New Zealand Blood Service sites between 3rd December 2020 and 6th January 2021.







Conclusions:

- The very low seroprevalence of SARS-CoV-2 infection in New Zealand implies undetected community transmission has been limited¹.
- This study highlights the value of a nationwide blood donor service to monitor viral spread during the pandemic.

References:

- ¹Carlton *et al* (2021). Charting Elimination in a Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand. Epidemiology and Infection (in press).
- ²McGregor and Whitcombe et al (2020). Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand. PeerJ. 8:e9863.
- ³Tan et al (2020). A SARS-CoV-2 surrogate virus neutralisation test based on antibody-mediated blockage of ACE-2-spike protein-protein interaction. Nature Biotechnology. 38:1073-1078.
- ⁴Whitcombe *et al* (2021). Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. Clinical and Transnational Immunology. 10(3):e1261.